(2R,3R,4S,5S,6R)-6-(Hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,3,5-triol

Term ID

CHEBI:151352

Synonyms

beta-D-galacto-hexopyranosyl-(1->6)-beta-D-galacto-hexopyranosyl-(1->3)-beta-D-galacto-hexopyranose
Gal(b1-6)Gal(b1-3)b-Gal
WURCS=2.0/1,3,2/[a2112h-1b_1-5]/1-1-1/a3-b1_b6-c1

Definition

References

GlyGen:G55829QO
GlyTouCan:G55829QO

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3R,4S,5S,6R)-6-(Hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,3,5-triol

Phenotype where environments contain (2R,3R,4S,5S,6R)-6-(Hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,3,5-triol

Phenotype modified by environments containing (2R,3R,4S,5S,6R)-6-(Hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,3,5-triol

Phenotype affecting (2R,3R,4S,5S,6R)-6-(Hydroxymethyl)-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxane-2,3,5-triol

Human Disease Model